CA2750149C - System and method for ocular iontophoresis with buffering - Google Patents
System and method for ocular iontophoresis with buffering Download PDFInfo
- Publication number
- CA2750149C CA2750149C CA2750149A CA2750149A CA2750149C CA 2750149 C CA2750149 C CA 2750149C CA 2750149 A CA2750149 A CA 2750149A CA 2750149 A CA2750149 A CA 2750149A CA 2750149 C CA2750149 C CA 2750149C
- Authority
- CA
- Canada
- Prior art keywords
- layer
- delivery device
- buffer
- therapeutic substance
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000003139 buffering effect Effects 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 142
- 239000000126 substance Substances 0.000 claims abstract description 131
- 239000000872 buffer Substances 0.000 claims abstract description 130
- 239000012528 membrane Substances 0.000 claims abstract description 58
- 239000007853 buffer solution Substances 0.000 claims abstract description 54
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 239000006260 foam Substances 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 10
- 239000011148 porous material Substances 0.000 claims description 94
- 239000002245 particle Substances 0.000 claims description 27
- 239000000499 gel Substances 0.000 claims description 25
- 125000000129 anionic group Chemical group 0.000 claims description 19
- 239000006172 buffering agent Substances 0.000 claims description 18
- 125000002091 cationic group Chemical group 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- 239000003456 ion exchange resin Substances 0.000 claims description 12
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 12
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 239000006193 liquid solution Substances 0.000 claims description 9
- 230000005684 electric field Effects 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- 230000035699 permeability Effects 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 238000005342 ion exchange Methods 0.000 claims description 3
- 239000004964 aerogel Substances 0.000 claims description 2
- 108010025899 gelatin film Proteins 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 abstract description 30
- 239000007788 liquid Substances 0.000 abstract description 24
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000010410 layer Substances 0.000 description 125
- 238000002360 preparation method Methods 0.000 description 47
- 239000008186 active pharmaceutical agent Substances 0.000 description 43
- -1 for example Substances 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000001508 eye Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000005414 inactive ingredient Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000001788 irregular Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000003957 anion exchange resin Substances 0.000 description 5
- 239000003729 cation exchange resin Substances 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012928 buffer substance Substances 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003014 ion exchange membrane Substances 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 239000002088 nanocapsule Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000002077 nanosphere Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 2
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 2
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 2
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 2
- 239000007991 ACES buffer Substances 0.000 description 2
- 239000007988 ADA buffer Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 239000007992 BES buffer Substances 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 229940023913 cation exchange resins Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229920001897 terpolymer Polymers 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- MXRGSJAOLKBZLU-UHFFFAOYSA-N 3-ethenylazepan-2-one Chemical compound C=CC1CCCCNC1=O MXRGSJAOLKBZLU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940075534 amino methacrylate copolymer Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 150000007521 triprotic acids Chemical group 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0026—Ophthalmic product dispenser attachments to facilitate positioning near the eye
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0444—Membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Electrotherapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14199408P | 2008-12-31 | 2008-12-31 | |
| US61/141,994 | 2008-12-31 | ||
| US18060209P | 2009-05-22 | 2009-05-22 | |
| US61/180,602 | 2009-05-22 | ||
| PCT/US2009/069580 WO2010078246A1 (en) | 2008-12-31 | 2009-12-28 | System and method for ocular iontophoresis with buffering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2750149A1 CA2750149A1 (en) | 2010-07-08 |
| CA2750149C true CA2750149C (en) | 2018-02-27 |
Family
ID=42310178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2750149A Expired - Fee Related CA2750149C (en) | 2008-12-31 | 2009-12-28 | System and method for ocular iontophoresis with buffering |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9180292B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2370155B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5723293B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102341146B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009332951B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2750149C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2679673T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL213796A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011006925A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010078246A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5723293B2 (ja) * | 2008-12-31 | 2015-05-27 | アイゲート・ファーマシューティカルズ・インコーポレーテッドＥｙｅｇａｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 緩衝系を用いた経眼イオントフォレシスの装置および方法 |
| EP2663281B1 (en) * | 2011-01-12 | 2016-08-10 | Sooft Italia Spa | Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions |
| EP2753395B1 (en) * | 2011-09-09 | 2020-07-29 | International Scientific Pty Ltd | Method and device for delivery of substances |
| ITVE20130043A1 (it) * | 2013-07-31 | 2015-02-01 | I A C E R S R L | Dispositivo perfezionato oftalmologico per il trattamento di malattie corneali quali il cheratocono. |
| ES2672327T3 (es) * | 2014-01-27 | 2018-06-13 | Opia Technologies | Dispositivo de iontoforesis ocular |
| MX2017009193A (es) | 2015-01-22 | 2017-12-12 | Eyegate Pharmaceuticals Inc | Lente de contacto iontoforetica. |
| US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
| WO2018107200A1 (en) | 2016-12-13 | 2018-06-21 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
| CN113543753B (zh) * | 2019-03-04 | 2024-04-19 | 国立大学法人东北大学 | 眼用医疗器械的水分的吸收或排出方法及眼用医疗器械 |
| IT201900010341A1 (it) | 2019-06-27 | 2020-12-27 | Vision Eng Italy Srl | Dispositivo, sistema e metodo di trattamento di un tessuto corneale |
| US20240167531A1 (en) * | 2019-11-14 | 2024-05-23 | Siemens Gamesa Renewable Energy A/S | Damper for a wind turbine |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US551880A (en) | 1895-12-24 | Theodore b | ||
| SU654254A2 (ru) | 1977-02-07 | 1979-03-30 | В. Н. Серов | Устройство дл лечени глаз |
| SU995783A1 (ru) | 1980-07-21 | 1983-02-15 | Омский Государственный Ордена Трудового Красного Знамени Медицинский Институт Им.М.И.Калинина | Устройство дл электрофореза лекарственных веществ в ткани глаза |
| US4678466A (en) | 1981-06-25 | 1987-07-07 | Rosenwald Peter L | Internal medication delivery method and vehicle |
| SU1342500A1 (ru) | 1982-03-09 | 1987-10-07 | Омский государственный медицинский институт им.М.И.Калинина | Способ лечени глаукомы |
| US5053000A (en) | 1985-11-13 | 1991-10-01 | Imperial Chemical Industries Plc | Ocular treatment |
| US4752285B1 (en) | 1986-03-19 | 1995-08-22 | Univ Utah Res Found | Methods and apparatus for iontophoresis application of medicaments |
| IL86076A (en) | 1988-04-14 | 1992-12-01 | Inventor S Funding Corp Ltd | Transdermal drug delivery device |
| US4955378A (en) | 1988-05-02 | 1990-09-11 | University Of South Florida | Apparatus and methods for performing electrofusion at specific anatomical sites |
| AU5354190A (en) | 1989-03-17 | 1990-10-22 | Candela Laser Corporation | Non-invasive sclerostomy laser apparatus and method |
| US5174304A (en) | 1990-02-16 | 1992-12-29 | Latina Mark A | Electrocycloablation apparatus and method |
| CA2122150A1 (en) | 1991-08-26 | 1993-03-04 | Yie W. Chien | Iontotherapeutic device and process |
| US5533971A (en) | 1993-09-03 | 1996-07-09 | Alza Corporation | Reduction of skin irritation during electrotransport |
| US5420109A (en) | 1993-11-12 | 1995-05-30 | Houghten Pharmaceuticals, Inc. | Cytokine restraining agents |
| US5472436A (en) | 1994-07-26 | 1995-12-05 | Fremstad; Daria A. | Ocular appliance for delivering medication |
| AUPM982694A0 (en) | 1994-12-02 | 1995-01-05 | University Of Queensland, The | Iontophoresis method and apparatus |
| US5980497A (en) | 1996-03-15 | 1999-11-09 | Yavitz; Edward Q. | Membrane shield for eyes |
| JP3459724B2 (ja) * | 1996-03-17 | 2003-10-27 | 久光製薬株式会社 | イオントフォレーシス用電極デバイス |
| US5676648A (en) | 1996-05-08 | 1997-10-14 | The Aps Organization, Llp | Iontophoretic drug delivery apparatus and method for use |
| JPH1072374A (ja) * | 1996-06-20 | 1998-03-17 | Hisamitsu Pharmaceut Co Inc | イオントフォレーシス用薬物投与組成物 |
| DE69804921T2 (de) | 1997-10-28 | 2002-11-07 | Mecanismos Auxiliares Industriales, S.A. M.A.I.S.A. | Anschlusselement für eine Leiterplatte |
| FR2773320B1 (fr) | 1998-01-05 | 2000-03-03 | Optisinvest | Dispositif pour le transfert intraoculaire de produits actifs par iontophorese |
| BR0008123A (pt) | 1999-02-10 | 2001-11-13 | Gmp Drug Delivery Inc | Dispositivo baseado em emplastro para aumentar aliberação local de um agente de tratamento paradentro de tecidos alvo, e, processo de liberaçãode um agente de tratamento para dentro detecidos alvo de uma vesìcula corporal |
| TW539564B (en) | 1999-05-25 | 2003-07-01 | Iomed Inc | Methods and apparatus for ocular iontophoresis |
| US20030023228A1 (en) * | 2001-07-20 | 2003-01-30 | Parkinson Thomas M. | Ocular iontophoretic device and method for using the same |
| FR2830766B1 (fr) | 2001-10-12 | 2004-03-12 | Optis France Sa | Dispositif de delivrance de medicaments par iontophorese transpalpebrale |
| KR20050108345A (ko) | 2003-01-24 | 2005-11-16 | 컨트롤 딜리버리 시스템즈 인코포레이티드 | 탄산 탈수효소 저해제의 안구 전달을 위한 서방 장치와방법 |
| US20050197618A1 (en) * | 2004-03-03 | 2005-09-08 | Iomed, Inc. | Improved buffer gel for iontophoresis electrodes |
| FR2869531B1 (fr) | 2004-04-30 | 2006-07-14 | Optis France Sa Sa | Dispositif de iontophorese oculaire diminuant les irritations |
| AU2005247122C1 (en) | 2004-04-30 | 2012-02-02 | Eyegate Pharma S.A. | Irritation-reducing ocular iontophoretic device |
| KR20080066712A (ko) * | 2005-09-30 | 2008-07-16 | 티티아이 엘뷰 가부시키가이샤 | 관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법 |
| US8099162B2 (en) * | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
| US8321008B2 (en) * | 2005-11-30 | 2012-11-27 | Nitric Biotherapeutics, Inc. | Combination cartridge and device for electrokinetic delivery of medicament to a treatment site |
| KR20090106492A (ko) | 2006-12-01 | 2009-10-09 | 티티아이 엘뷰 가부시키가이샤 | 경피성 전달 장치와 같은 장치에 전력을 제공하거나 제어하기 위한 시스템, 장치, 및 방법 |
| CN101970042A (zh) * | 2008-02-25 | 2011-02-09 | 眼门药品公司 | 经由离子电渗法增强递送治疗药物至眼部组织 |
| JP5723293B2 (ja) * | 2008-12-31 | 2015-05-27 | アイゲート・ファーマシューティカルズ・インコーポレーテッドＥｙｅｇａｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 緩衝系を用いた経眼イオントフォレシスの装置および方法 |
-
2009
- 2009-12-28 JP JP2011544556A patent/JP5723293B2/ja active Active
- 2009-12-28 US US13/141,810 patent/US9180292B2/en not_active Expired - Fee Related
- 2009-12-28 CN CN200980157719.3A patent/CN102341146B/zh not_active Expired - Fee Related
- 2009-12-28 AU AU2009332951A patent/AU2009332951B2/en not_active Ceased
- 2009-12-28 CA CA2750149A patent/CA2750149C/en not_active Expired - Fee Related
- 2009-12-28 EP EP09837075.2A patent/EP2370155B1/en not_active Not-in-force
- 2009-12-28 WO PCT/US2009/069580 patent/WO2010078246A1/en not_active Ceased
- 2009-12-28 ES ES09837075.2T patent/ES2679673T3/es active Active
- 2009-12-28 MX MX2011006925A patent/MX2011006925A/es active IP Right Grant
-
2011
- 2011-06-28 IL IL213796A patent/IL213796A0/en unknown
-
2015
- 2015-11-02 US US14/930,193 patent/US9539141B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2679673T3 (es) | 2018-08-30 |
| CN102341146B (zh) | 2015-09-23 |
| US9180292B2 (en) | 2015-11-10 |
| EP2370155B1 (en) | 2018-07-04 |
| JP2012513875A (ja) | 2012-06-21 |
| AU2009332951A1 (en) | 2011-07-14 |
| US20110301526A1 (en) | 2011-12-08 |
| MX2011006925A (es) | 2011-07-28 |
| JP5723293B2 (ja) | 2015-05-27 |
| EP2370155A4 (en) | 2012-12-26 |
| WO2010078246A1 (en) | 2010-07-08 |
| AU2009332951B2 (en) | 2015-06-11 |
| US9539141B2 (en) | 2017-01-10 |
| IL213796A0 (en) | 2011-07-31 |
| EP2370155A1 (en) | 2011-10-05 |
| CA2750149A1 (en) | 2010-07-08 |
| US20160120696A1 (en) | 2016-05-05 |
| CN102341146A (zh) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2750149C (en) | System and method for ocular iontophoresis with buffering | |
| JP3549540B2 (ja) | 電気的移送式投与中の皮膚刺激状態の軽減 | |
| JP4414517B2 (ja) | イオントフォレーシス用デバイス構造体 | |
| US20070110810A1 (en) | Transdermal drug delivery systems, devices, and methods employing hydrogels | |
| US20070093788A1 (en) | Iontophoresis method and apparatus for systemic delivery of active agents | |
| JP2009509685A (ja) | 損傷組織の治癒を増強するための血管新生因子の送達のためのイオントフォレーシス装置及び方法 | |
| CN101965212A (zh) | 通过离子电渗疗法递送siRNA的方法 | |
| BRPI0923829A2 (pt) | Dispositivo de liberação | |
| AU2005239833B2 (en) | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds | |
| US20050142531A1 (en) | Peptidically buffered formulations for electrotransport applications and methods of making | |
| KR20170004683A (ko) | 아모롤핀을 포함하는 이온토포레시스 장치 및 그를 사용하여 아모롤핀을 전달하는 방법 | |
| WO2008116143A2 (en) | Water electrolysis to facilitate drug delivery by iontophoresis | |
| MX2008004224A (es) | Metodo y aparato de iontoforesis para el suministro sistemico de agentes activos | |
| HK1153419A (en) | Methods for delivering sirna via iontophoresis | |
| HK1098048B (en) | Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141211 |
|
| MKLA | Lapsed |
Effective date: 20201229 |